Preliminary Program
Preliminary Program: SUNDAY MAY22
Psychiatric News
Volume 40 Number 4 page 7-9

7:30 a.m.-5 p.m.

Registration/Course Enrollment Open

8 a.m.-11 a.m.

Industry-Supported Symposia IS11. Systemic Treatment of Bipolar Disorder: Bringing Evidence Into PracticeSupported by GlaxoSmithKline

A. Approach to Treatment: Integration of Measurement and Management Andrew A. Nierenberg, M.D.

B. View of the Illness: Course and Comorbidity Findings Claudia F. Baldassano, M.D.

C. What Is the Best Treatment for Manic and Mixed Episodes? Gary S. Sachs, M.D.

D. What Is the Best Treatment for Bipolar Depression? Michael J. Ostacher, M.D.

E. What Is the Best Treatment for Rapid Cycling? Christopher D. Schneck, M.D.

F. Managing Comorbidity Michael J. Ostacher, M.D.

G. Psychosocial Interventions David J. Miklowitz, Ph.D.

H. Multiphase Suicide Prevention Strategies in Bipolar Disorder Ellen B. Dennehy, Ph.D.

IS12. Too Little, Too Much: What Is Disordered Eating?Supported by OrthoMcNeil Pharmaceuticals

A. Medical Morbidity of Eating Disorders Laurel Mayer, M.D.

B. Genetic Epidemiology of Disordered Eating James I. Hudson, M.D.

C. Psychiatric Comorbidity of Eating Disorders: Understanding the Contribution of Impulsivity Susan L. McElroy, M.D.

D. Psychotherapy for Eating Disorders Cynthia M. Bulik, Ph.D.

E. New Trends in the Pharmacologic Treatment of Eating Disorders Scott J. Crow, M.D.

IS13. Spotlight on the Uniqueness of Depression and Anxiety in the ElderlySupported by Forest Laboratories Inc.

A. Late-Onset Depression: A Distinctive Disease Associated With the Elderly Steven P. Roose, M.D.

B. Recognizing Depressive Disorders Comorbid With Medical Illnesses in the Elderly Eric Lenze, M.D.

C. Bereavement-Related Depression and Anxiety M. Katherine Shear, M.D.

D. Antidepressants and Anxiolytics in the Elderly: A Focus on Safety George S. Alexopoulos, M.D.

IS14. Brain Stimulation: New Treatments for Mood DisordersSupported by Cyberonics Inc.

A. Optimizing the Therapeutic Elements of ECT Harold A. Sackeim, Ph.D.

B. Current Status of Repeated Transcranial Magnetic Stimulation Mark S. George, M.D.

C. Current Status of Magnetic Stimulation Therapy (MST) Sarah H. Lisanby, M.D.

D. Current Status of Vagus Nerve Stimulation (VNS) Lauren B. Marangell, M.D.

E. Current Status of Deep Brain Stimulation Benjamin D. Greenberg, M.D.

IS15. Panic Disorder: Current Concepts and Future DirectionsSupported by Wyeth Pharmaceuticals

A. Window Into the Brain: Imaging Panic Disorder and the Neurocircuitry of Fear Justine M. Kent, M.D.

B. Genetics of Panic Disorder: What Have We Learned? Jordan W. Smoller, M.D.

C. Cross-Cultural Aspects of Panic and Other Anxiety Disorders Michael R. Liebowitz, M.D.

D. Panic Symptoms and the Interface of Mind and Body Karleyton C. Evans, M.D.

E. Treating Panic Disorder: Acute Therapy and Beyond Mark H. Pollack, M.D.

IS16. Antipsychotic Drugs, Mood Stabilizers, and the Metabolic SyndromeSupported by Janssen Pharmaceutica Products

A. Effects of Atypical Antipsychotics on Weight Gain, Glucose Metabolism, and Diabetes Mellitus Dan W. Haupt, M.D.

B. The Effect of Antipsychotic Drugs on Lipids and Other Elements of the Metabolic Syndrome Herbert Y. Meltzer, M.D.

C. Insulin Resistance, Dyslipidemia, and Cardiovascular Disease Gerald Reaven, M.D.

D. Metabolic Sequelae of Atypical Antipsychotics: Obesity and Type II Diabetes Marilyn Ader, Ph.D.

E. A Clinician's Guide to Managing Cardiac Risk Factors Donald C. Goff, M.D.

IS17. BPD: Pathophysiology Treatment and CourseSupported by Eli Lilly and Company

A. 10-Year Course of BPD Mary Zanarini, Ed.D.

B. Neurobiology of BPD: An Update Christian Schmahl, M.D.

C. BPD: Pharmacotherapy Steps Up S. Charles Schulz, M.D.

D. Neural Circuitry Dysfunction in BPD Antonia S. New, M.D.

E. Update on Dialectical Behavior Therapy for BPD Marsha Lineham, Ph.D.

8 a.m.-Noon

CME Courses 13-19

9 a.m.-4 p.m.

CME Courses 20-25

10 a.m.-4:30 p.m.

Exhibits Open APA Member Center Open Publishers' Bookfair Open

12:30 p.m.-1:30 p.m.

Business Meeting and Forum (voting members only)

1 p.m.—5 p.m.

CME Courses 26-32

1:30 p.m.-4:30 p.m.

Industry-Supported Symposia IS18. Joining Night and Day: Insomnia and the Sleep/Wake CycleSupported by Takeda Pharmaceuticals North America Inc.

A. Insomnia: Prevalence, Impact, and Current Approaches to Evaluation and Management Karl Doghramji, M.D.

B. Medical Causes of Insomnia Gerald A. Maguire, M.D.

C. Circadian Rhythm Alterations in Psychiatric Disorders Alfred J. Lewy, M.D.

D. Current and Emerging Insomnia Treatments Milton K. Erman, M.D.

E. Special Concerns in Aging Populations Sonia Ancoli-Israel, Ph.D.

IS19. Clinical Interventions for the Treatment of Insomnia Associated With Psychiatric and Comorbid Medical IllnessesSupported by Neurocrine Biosciences Inc.

A. Interrelationship of Insomnia to Medical Illnesses and Neurological Disorders Phyllis C. Zee, M.D.

B. Effect of Chronic Pain Syndromes on Sleep Raymond R. Gaeta, M.D.

C. Clinical Approaches to Insomnia David J. Kupfer, M.D.

D. Gender-Specific Sleep Considerations in Women Hadine Joffe, M.D.

E. New Pharmacologic Approaches for the Treatment of Insomnia John W. Winkelman, M.D.

IS20. Alzheimer's Disease Pathways to Practice: Assessing Diagnosis and Outcome MeasuresSupported by Forest Laboratories Inc.

A. The Interplay of Neurotransmitters in Alzheimer's Disease Paul T. Francis, Ph.D.

B. Formulating a Clinical Practice Care Plan for the Diagnosis and Assessment of Alzheimer's Disease Warachal E. Faison, M.D.

C. Imaging the Pathology of Alzheimer's Disease With Pittsburgh Compound-B Mark A. Mintum, M.D.

D. Rationalizing Therapeutic Approaches in Alzheimer's Disease George T. Grossberg, M.D.

IS21. Anxiety Disorders: Understanding the Interconnection Between Emotional and Physical SymptomsSupported by Wyeth Pharmaceuticals

A. Worried Sick: How Patients Experience GAD R. Bruce Lydiard, M.D.

B. Addressing the Full Spectrum of Symptoms of Social Anxiety Disorder Nathalie Maullin, M.D.

C. Pharmacotherapy and Psychotherapy in the Treatment of PTSD Barbara Rothbaum, Ph.D.

D. Panic Disorder: The Interconnection Between Emotional and Physical Symptoms Mark H. Rapaport, M.D.

IS22. Relapse Prevention in Schizophrenia: From Biology to Functional RecoverySupported by Janssen Pharmaceutica and Research Foundation

A. The Neurochemistry of Relapse in Schizophrenia Robert B. Zipursky, M.D.

B. Defining the Key Clinical Parameters That Contribute to Relapse in Schizophrenia Stefan M. Leucht, M.D.

C. Can Relapse Be Prevented Through Pharmacological Intervention? John M. Kane, M.D.

D. Remission and Functional Recovery in Schizophrenia: Raising the Bar for Clinical Outcomes Nina R. Schooler, Ph.D.

IS23. Fibromyalgia: A Disorder at the Medicine and Psychiatry InterfaceSupported by Pfizer Inc.

A. The Pathophysiological Basis of Fibromyalgia: Emerging Evidence Daniel J. Clauw, M.D.

B. Management of Psychiatric Comorbidity in Patients With Fibromyalgia Lesley M. Arnold, M.D.

C. Recent Developments in the Pharmacotherapy of Fibromyalgia Leslie J. Crofford, M.D.

D. Nonpharmacological Treatment of Fibromyalgia Shay B. Stanford, M.D.

2:30 p.m.-4 p.m.


L1. Assessing and Managing Suicide Risk: Guidelines for Clinically Based Risk ManagementRobert I. Simon, M.D., AAPL/APA's Manfred S. Guttmacher Award Lecture

5 p.m.-6:30 p.m.

Opening Session and Presidential Address

7 p.m.-10 p.m.

Industry-Supported Symposia IS24. Exploring Cognitive Function: From Brain to BedsideSupported by Cephalon Inc.

A. The Neurology of Cognition: A Glimpse Into the Brain Daniel R. Weinberger, M.D.

B. Remission in Major Depression: The Vitality of Cognition Philip T. Ninan, M.D.

C. Can Clinicians Impact Cognition in Schizophrenia? Rona Hu, M.D.

D. The Complexities of Cognitive Dysfunction in Late-Life Depression George S. Alexopoulos, M.D.

E. The Evidence and Relevance of Cognitive Dysfunction Scott Kollins, Ph.D.

IS25. Bipolar Disorder: Treating Through the Entire SpectrumSupported by AstraZeneca Pharmaceuticals

A. The Neuroscience of Bipolar Disorder Across the Age Spectrum Kiki D. Chang, M.D.

B. Issues in Treating Bipolar Depression Joseph R. Calabrese, M.D.

C. The Acute Setting: Achieving Stabilization Trisha Suppes, M.D.

D. From Acute to Maintenance Therapy Gary S. Sachs, M.D.

IS26. Untangling Depression and Anxiety: A Challenge for Scientists and CliniciansSupported by Forest Laboratories Inc.

A. Genetic Models of Depression and Anxiety Rene Hen, Ph.D.

B. Serotonergic Targets as Mediators of Anxiety Alexander Neumeister, M.D.

C. Neuroanatomical Pathways Underlying Mood and Anxiety Disorders Wayne C. Drevets, M.D.

D. Presentation and Diagnosis of Comorbid MDD and Anxiety Disorder Naomi M. Simon, M.D.

E. Making Treatment Decisions for Comorbid MDD and Anxiety Disorder Martin B. Keller, M.D.

IS27. ADHD Through the Life Cycle: New Findings and Clinical ImplicationsSupported by Shire US Inc.

A. Adult ADHD Diagnostic and Self-Report Symptom Scales: Assessment Methodology for Diagnosing and Monitoring Treatment of Adults With ADHD Craig B. Surman, M.D.

B. Functional Impairments in Adult ADHD: Implications for Diagnosis Stephen V. Faraone, Ph.D.

C. Long-Term Tolerability and Effectiveness of Once-Daily, Mixed Amphetamine Salts in Children With ADHD Thomas J. Spencer, M.D.

D. Long-Term Outcome of Adults Treated With Mixed Amphetamine Salts Extended Release Joseph Biederman, M.D.

E. New Research on ADHD and Substance Use Disorders Timothy E. Wilens, M.D.

IS28. Emerging Best Practices in the Management of Behavioral EmergenciesSupported by Bristol-Myers Squibb Company

A. Is Agitation Inevitably a Precursor to Aggression? Heather A. Wood, M.D.

B. Assessment of the Acutely Agitated Patient With Psychosis Joseph P. McEvoy, M.D.

C. Considering Consumer Choice During the Management of Behavioral Emergencies Michael H. Allen, M.D.

D. Do Atypical Antipsychotics Work Fast Enough in Behavioral Emergencies? Robert B. Zipursky, M.D.

E. Acute Stabilization With Atypical Antipsychotics: New Therapeutic Options Peter F. Buckley, M.D.

IS29. Beyond Neurochemistry: The Implications of Neurocircuitry for Understanding and Managing Psychiatric DisordersSupported by Eli Lilly and Company

A. Neuroanatomy of Behavior 101 Paula T. Trzepacz, M.D.

B. Neurocircuitry of Schizophrenia David A. Lewis, M.D.

C. Neurobiological Substrates of ADHD George Bush, M.D.

D. In Search of Depression Circuits Helen S. Mayberg, M.D.

E. Neural Pathways and Behavior in Anorexia Nervosa Walter H. Kaye, M.D.

IS30. From Molecular Insight to Clinical Outcomes: Recent Advances in Schizophrenia TreatmentSupported by Pfizer Inc.

A. How Antipsychotics Work From Receptors to Reality Shitij Kapur, M.D.

B. Clinical Effectiveness of Atypical Antipsychotic Therapy Thomas S. Stroup, M.D.

C. Cognitive Effectiveness of Atypical Antipsychotic Therapy Philip D. Harvey, Ph.D.

D. Enhancing Clinical Care in Schizophrenia: Primary Health Care Needs Gail L. Daumit, M.D.

E. Translating Scientific Research Into Clinical Practice Jeffrey A. Lieberman, M.D.

Anchor for JumpAnchor for Jump

Piedmont Park, at 185 acres, is Atlanta's largest park and features the Atlanta Botanical Gardens. It is the site of numerous cultural events, festivals, Atlanta Symphony Orchestra concerts, and more.  © 2003, Kevin C.Rose/AtlantaPhotos.com

Anchor for JumpAnchor for Jump

Piedmont Park, at 185 acres, is Atlanta's largest park and features the Atlanta Botanical Gardens. It is the site of numerous cultural events, festivals, Atlanta Symphony Orchestra concerts, and more.  © 2003, Kevin C.Rose/AtlantaPhotos.com

Interactive Graphics


Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Related Articles